TIDMGEN
Company Announcement
COPENHAGEN, Denmark; March 27, 2023 --
https://www.globenewswire.com/Tracker?data=E-fMXsJAV3-RVAfvs6EasYRWnHYFt1ipA59kjSzk4zWZQzFb4hR1urLk24gNpgbv9dhFhZBSSk1tnSQYKXuIlw==
Genmab A/S (Nasdaq: GMAB). On February 22, 2023, Genmab announced
the initiation of a share buy-back program to honor our commitments
under our Restricted Stock Units program.
The share buy-back program is expected to be completed no later
than March 31, 2023, and comprises up to 220,000 shares.
The following transactions were executed under the program from
March 20, 2023, to March 24, 2023:
Average price
No. of shares (DKK) Total value (DKK)
------------------------- ------------- ------------- -----------------
Accumulated through last
announcement 167,000 427,631,620
March 20, 2023 6,000 2,504.24 15,025,440
March 21, 2023 5,000 2,541.77 12,708,850
March 22,2023 5,000 2,541.44 12,707,200
March 23, 2023 7,000 2,529.99 17,709,930
March 24, 2023 7,000 2,564.91 17,954,370
Total 30,000 76,105,790
Accumulated under the
program 197,000 503,737,410
Details of each transaction are included as an appendix to this
announcement.
Following these transactions, Genmab holds 740,416 shares as
treasury shares, corresponding to 1.12% of the total share capital
and voting rights.
The share buy-back program is undertaken in accordance with
Regulation (EU) No. 596/2014 ('MAR') and the Commission Delegated
Regulation (EU) 2016/1052, also referred to as the "Safe Harbour
Regulation." Further details on the terms of the share buy-back
program can be found in our company announcement no. 06 dated
February 22, 2023.
About Genmab
Genmab is an international biotechnology company with a core
purpose guiding its unstoppable team to strive towards improving
the lives of patients through innovative and differentiated
antibody therapeutics. For more than 20 years, its passionate,
innovative and collaborative team has invented next-generation
antibody technology platforms and leveraged translational research
and data sciences, which has resulted in a proprietary pipeline
including bispecific T-cell engagers, next-generation immune
checkpoint modulators, effector function enhanced antibodies and
antibody-drug conjugates. To help develop and deliver novel
antibody therapies to patients, Genmab has formed 20+ strategic
partnerships with biotechnology and pharmaceutical companies. By
2030, Genmab's vision is to transform the lives of people with
cancer and other serious diseases with Knock-Your-Socks-Off (KYSO)
antibody medicines.
Established in 1999, Genmab is headquartered in Copenhagen,
Denmark with locations in Utrecht, the Netherlands, Princeton, New
Jersey, U.S. and Tokyo, Japan. For more information, please visit
https://www.globenewswire.com/Tracker?data=E-fMXsJAV3-RVAfvs6EasXNRiiIpgUfkQFyWl9Hzenn6Q0a5ytkAxwAQR9s0HtgRLZj5Qhs_YSAVeltVybBBXg==
Genmab.com and follow us on
https://www.globenewswire.com/Tracker?data=N5gb_-8Uj7NfDIVQnvCFxb5MAajb9JtYC7WPyrJkeygXzDBq8TWQt8P6Yx59nMCWU50UKfgkaI7P9JBLmUpcsqysd2Wjggz2CGYwbL04yas=
Twitter.com/Genmab.
Contact:
Marisol Peron, Senior Vice President, Global Communications and
Corporate Affairs
T: +1 609 524 0065; E:
https://www.globenewswire.com/Tracker?data=YuUbE_dVMa-G40KF7BJ0LZ9h6lz7gr46izLSPdnQWDHv1nDR49EFYs0lfJ0siB7rM_HRQkK9hEQziUdwOQyv_A==
mmp@genmab.com
Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E:
https://www.globenewswire.com/Tracker?data=G73s7MZ3ZAjcMJPMib2T9AkDFHPbfFU1b9tVn0uBPPOmuCBUI1qSVbDkWFNRPpWjfsVrB42NgKUmV6pZ_zxWQw==
acn@genmab.com
This Company Announcement contains forward looking statements.
The words "believe", "expect", "anticipate", "intend" and "plan"
and similar expressions identify forward looking statements. Actual
results or performance may differ materially from any future
results or performance expressed or implied by such statements. The
important factors that could cause our actual results or
performance to differ materially include, among others, risks
associated with pre-clinical and clinical development of products,
uncertainties related to the outcome and conduct of clinical trials
including unforeseen safety issues, uncertainties related to
product manufacturing, the lack of market acceptance of our
products, our inability to manage growth, the competitive
environment in relation to our business area and markets, our
inability to attract and retain suitably qualified personnel, the
unenforceability or lack of protection of our patents and
proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our
products or technologies obsolete, and other factors. For a further
discussion of these risks, please refer to the risk management
sections in Genmab's most recent financial reports, which are
available on
https://www.globenewswire.com/Tracker?data=3zHPrR1tanidBW0azj9qNgd1oFybVhnG2FMzSJ6Vzy5jGy2CNnjGZ_pt7gGSmDU_KrFH0yCCaWgSm9aW7AF_vw==
www.genmab.com and the risk factors included in Genmab's most
recent Annual Report on Form 20-F and other filings with the U.S.
Securities and Exchange Commission (SEC), which are available at
https://www.globenewswire.com/Tracker?data=3zHPrR1tanidBW0azj9qNjLo8hNci1suuAYaOk8W0C-cueeO0pIZkmHV-Q6HK2yCJicVVEyalalzIe0xwQyo0-DG-ppoPJSY-xLiaUo1kPU=
www.sec.gov. Genmab does not undertake any obligation to update or
revise forward looking statements in this Company Announcement nor
to confirm such statements to reflect subsequent events or
circumstances after the date made or in relation to actual results,
unless required by law.
Genmab A/S and/or its subsidiaries own the following trademarks:
Genmab(R) ; the Y-shaped Genmab logo(R) ; Genmab in combination
with the Y-shaped Genmab logo(R) ; HuMax(R) ; DuoBody(R) ; DuoBody
in combination with the DuoBody logo(R) ; HexaBody(R) ; HexaBody in
combination with the HexaBody logo(R) ; DuoHexaBody(R) and
HexElect(R) .
Company Announcement no. 16
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122
Genmab A/S
Kalvebod Brygge 43
1560 Copenhagen V
Denmark
Attachments
-- CA16_Transactions in connections with share buyback program - Mar 24 2023
https://ml-eu.globenewswire.com/Resource/Download/c48c457e-e34c-4a69-981b-5981106b0a89
-- Appendix_SBBP_specification for March 20 to March 24
https://ml-eu.globenewswire.com/Resource/Download/440a4a1f-25aa-4c50-9933-6a1178886ddb
(END) Dow Jones Newswires
March 27, 2023 09:00 ET (13:00 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Genuit (LSE:GEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genuit (LSE:GEN)
Historical Stock Chart
From Apr 2023 to Apr 2024